Bill · S. 3551· Senate(119-S-3551)
PROTECT for Rare Act
- Introduced
- 12/17/2025
- Last activity
- 12/17/2025 — Read twice and referred to the Committee on Finance.
- Sponsored by
- Thomas Tillis
- Cosponsors
- - 0 - 1
- Introduced
- In Committee
What this bill would do
This bill is called the Providing Realistic Opportunity To Equal and Comparable Treatment for Rare Act or the PROTECT for Rare Act. It aims to update coverage rules for certain drugs used to treat rare diseases or conditions affecting 200,000 or fewer people in the United States. The legislation covers programs under Medicare, Medicaid, and private health insurance. Under the bill, qualifying uses for rare disease drugs must be supported by medical literature, clinical guidelines, or medical experts. It also sets up an expedited review process for private health insurance coverage denials regarding these specific drugs. The changes outlined in the bill are scheduled to take effect starting on January 1, 2027.
Yes· 3 of 14
Would people with disabilities be better off under this?+7
Provides substantial benefits to individuals with severe or rare medical conditions and disabilities by securing treatment access.
Does this make health care easier to get in general?+7
Improves healthcare access by clarifying and expanding coverage pathways for specialized rare disease medications across Medicare, Medicaid, and private insurance.
Would people over 65 be better off under this?+6
Directly benefits seniors by updating Medicare definitions to explicitly cover qualifying rare disease treatments.
The opposite
No question was scored the opposite.
Who it would affect, and how
Potential Positive Impacts for People
-
Section 2(a) updates Medicare rules to explicitly include coverage for certain drugs used to treat rare diseases or conditions affecting 200,000 or fewer individuals, provided the use is supported by peer-reviewed medical literature or clinical guidelines. This is positive because it helps Medicare patients access necessary treatments for rare conditions.
-
Section 2(b) updates the definition of medically accepted indications under Medicaid for drugs treating rare diseases or conditions affecting 200,000 or fewer individuals based on peer-reviewed literature, clinical guidelines, or medical society experts. This helps lower-income individuals on Medicaid gain clearer coverage pathways for specialized rare disease medications.
-
Section 2(c) requires group health plans and health insurance issuers to provide an expedited appeal process for denied coverage of drugs used to treat rare diseases or conditions affecting 200,000 or fewer individuals. This benefits patients with private insurance by giving them a faster way to fight a coverage denial for their rare disease treatments.
Potential Negative Impacts for People
- The provided text does not contain explicit details regarding potential negative consequences or burdens for individuals or groups of people.
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Hover a score for the reason it gave.
- Demographic And Interest Groups
- Good For People With Disabilities+7Good For Low Income Households+6Good For Retirees+6Good For Seniors+6Good For Children+5Good For Middle Aged+5Good For Middle Class Households+5Good For Young Adults+5
- Healthcare
- Improves Healthcare Access+7Increases Medicaid Funding+5Increases Medicare Funding+5
- Governance And Ideology
- Improves Due Process+6Increases Federal Power+3
- Economy And Finance
- Improves Consumer Protection+6
- 12/17/2025
- Read twice and referred to the Committee on Finance.
- 1 Cosponsor added.
- Introduced in Senate
Martin HeinrichDemocrat · New Mexico